FindTrial
Sign In

TCD601

BIOLOGICAL8 trials

Sponsors

ITB-Med LLC

Conditions

ALSDiabetes Mellitus, Type 1Kidney TransplantationLiver TransplantationRenal Transplantation

Phase 1

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients
RecruitingNCT06453668
ITB-Med LLCALS
Start: 2024-04-16End: 2029-11-01Target: 48Updated: 2026-03-31

Phase 2

A Dose Escalation Study in de Novo Renal Transplantation
CompletedNCT04311632
ITB-Med LLCKidney Transplantation
Start: 2021-05-26End: 2023-10-03Updated: 2025-02-27
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
TerminatedNCT04803006
ITB-Med LLCKidney Transplantation
Start: 2023-01-17End: 2025-10-30Updated: 2026-02-06
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
Active, not recruitingNCT04803058
ITB-Med LLCKidney Transplantation
Start: 2022-12-14End: 2030-03-01Target: 18Updated: 2026-02-06
A Study of TCD601 in de Novo Renal Transplant Recipients
Active, not recruitingNCT05669001
ITB-Med LLCRenal Transplantation
Start: 2023-12-28End: 2026-04-30Updated: 2026-01-14
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
Active, not recruitingNCT06019507
ITB-Med LLCLiver Transplantation
Start: 2022-06-29End: 2029-06-30Target: 12Updated: 2024-11-27
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
TerminatedNCT06025110
ITB-Med LLCDiabetes Mellitus, Type 1
Start: 2023-01-23End: 2025-07-24Updated: 2025-08-14
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
TerminatedNCT06365437
ITB-Med LLCKidney Transplantation
Start: 2021-06-06End: 2024-12-11Updated: 2026-03-12